JP2018502126A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502126A5 JP2018502126A5 JP2017536934A JP2017536934A JP2018502126A5 JP 2018502126 A5 JP2018502126 A5 JP 2018502126A5 JP 2017536934 A JP2017536934 A JP 2017536934A JP 2017536934 A JP2017536934 A JP 2017536934A JP 2018502126 A5 JP2018502126 A5 JP 2018502126A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pulmonary
- activator
- bmpr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 claims 7
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 claims 7
- 208000002815 pulmonary hypertension Diseases 0.000 claims 7
- 239000012190 activator Substances 0.000 claims 5
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 4
- 229960000307 avanafil Drugs 0.000 claims 4
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical group C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 claims 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 229950005371 zaprinast Drugs 0.000 claims 4
- REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 claims 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 3
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 3
- 229940126514 guanylate cyclase activator Drugs 0.000 claims 3
- 239000003119 guanylate cyclase activator Substances 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 229960000438 udenafil Drugs 0.000 claims 3
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 claims 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 230000001882 diuretic effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229950002245 mirodenafil Drugs 0.000 claims 2
- MIJFNYMSCFYZNY-UHFFFAOYSA-N mirodenafil Chemical compound C1=C(C=2NC=3C(CCC)=CN(CC)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)N1CCN(CCO)CC1 MIJFNYMSCFYZNY-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229940127293 prostanoid Drugs 0.000 claims 2
- 150000003814 prostanoids Chemical class 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 229960003310 sildenafil Drugs 0.000 claims 2
- 229960001967 tacrolimus Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- 229960000835 tadalafil Drugs 0.000 claims 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 2
- 229960002381 vardenafil Drugs 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 101710158332 Diuretic hormone Proteins 0.000 claims 1
- 101710204261 Diuretic hormone class 2 Proteins 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010021133 Hypoventilation Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010025219 Lymphangioma Diseases 0.000 claims 1
- 206010070995 Vascular compression Diseases 0.000 claims 1
- 229960002414 ambrisentan Drugs 0.000 claims 1
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical group O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 claims 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 claims 1
- 229950010993 atrasentan Drugs 0.000 claims 1
- 229960003065 bosentan Drugs 0.000 claims 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000009547 development abnormality Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000004 hemodynamic effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- TUYWTLTWNJOZNY-UHFFFAOYSA-N n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2h-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=C(N=CC=2)C2=NNN=N2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)C)C=N1 TUYWTLTWNJOZNY-UHFFFAOYSA-N 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 229960000529 riociguat Drugs 0.000 claims 1
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical group N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 229960002578 sitaxentan Drugs 0.000 claims 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229950000584 tezosentan Drugs 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103020P | 2015-01-13 | 2015-01-13 | |
| US62/103,020 | 2015-01-13 | ||
| PCT/US2016/012694 WO2016114993A1 (en) | 2015-01-13 | 2016-01-08 | Combination therapy for pulmonary hypertension |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502126A JP2018502126A (ja) | 2018-01-25 |
| JP2018502126A5 true JP2018502126A5 (https=) | 2019-02-21 |
| JP6890540B2 JP6890540B2 (ja) | 2021-06-18 |
Family
ID=56406244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536934A Active JP6890540B2 (ja) | 2015-01-13 | 2016-01-08 | 肺高血圧症のための併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20180325875A1 (https=) |
| EP (1) | EP3244968B1 (https=) |
| JP (1) | JP6890540B2 (https=) |
| KR (1) | KR102569428B1 (https=) |
| CN (1) | CN107427698A (https=) |
| AU (1) | AU2016207046B2 (https=) |
| BR (1) | BR112017014914B1 (https=) |
| CA (1) | CA2973114C (https=) |
| IL (1) | IL253325A0 (https=) |
| MX (1) | MX2017009110A (https=) |
| NZ (1) | NZ733451A (https=) |
| WO (1) | WO2016114993A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| KR20260020212A (ko) * | 2016-11-10 | 2026-02-10 | 아레나 파마슈티칼스, 인크. | 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법 |
| EP4620525A3 (en) * | 2016-12-14 | 2025-12-03 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
| CN112569357B (zh) * | 2019-09-30 | 2023-03-28 | 深圳奥萨制药有限公司 | 双重内皮素受体拮抗剂与利尿剂的组合物 |
| CN114728002A (zh) * | 2019-11-29 | 2022-07-08 | 埃科特莱茵药品有限公司 | 治疗肺动脉高血压的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009152453A2 (en) * | 2008-06-12 | 2009-12-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating pulmonary hypertension |
| PL2704711T3 (pl) * | 2011-05-02 | 2021-07-05 | The Board Of Trustees Of The Leland Stanford Junior University | Zastosowanie fk506 w leczeniu tętniczego nadciśnienia płucnego |
| EP2707485B1 (en) * | 2011-05-09 | 2016-12-14 | The University Court of The University Of Glasgow | Methods of modulating micrornas in the treatment of pulmonary arterial hypertension |
| US9233089B2 (en) * | 2012-03-23 | 2016-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pulmonary hypertension with leukotriene inhibitors |
-
2016
- 2016-01-08 EP EP16737651.6A patent/EP3244968B1/en active Active
- 2016-01-08 JP JP2017536934A patent/JP6890540B2/ja active Active
- 2016-01-08 AU AU2016207046A patent/AU2016207046B2/en active Active
- 2016-01-08 MX MX2017009110A patent/MX2017009110A/es unknown
- 2016-01-08 CA CA2973114A patent/CA2973114C/en active Active
- 2016-01-08 BR BR112017014914-1A patent/BR112017014914B1/pt active IP Right Grant
- 2016-01-08 WO PCT/US2016/012694 patent/WO2016114993A1/en not_active Ceased
- 2016-01-08 CN CN201680015289.1A patent/CN107427698A/zh active Pending
- 2016-01-08 NZ NZ733451A patent/NZ733451A/en unknown
- 2016-01-08 US US15/543,510 patent/US20180325875A1/en not_active Abandoned
- 2016-01-08 KR KR1020177022273A patent/KR102569428B1/ko active Active
-
2017
- 2017-07-05 IL IL253325A patent/IL253325A0/en unknown
-
2019
- 2019-04-11 US US16/381,128 patent/US20200069658A1/en not_active Abandoned
-
2021
- 2021-05-11 US US17/317,274 patent/US20210267951A1/en not_active Abandoned
-
2024
- 2024-03-28 US US18/620,058 patent/US20240238259A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502126A5 (https=) | ||
| ES2544724T3 (es) | Composición para tratar una hipertensión pulmonar | |
| JP6170040B2 (ja) | ピルフェニドン及び選択された患者における抗線維化療法 | |
| JP6250671B2 (ja) | 免疫関連及び炎症性疾患の治療 | |
| JP2010512414A5 (https=) | ||
| JP5806320B2 (ja) | 肺高血圧症を処置するための組成物および方法 | |
| JP2008525476A5 (https=) | ||
| JP2015516392A5 (https=) | ||
| JPWO2023018809A5 (https=) | ||
| CN112055593A (zh) | 包含(2s)-n-{(1s)-1-氰基-2-[4-(3-甲基-2-氧代-2,3-二氢-1,3-苯并噁唑-5-基)苯基]乙基}-1,4-氧杂氮杂环庚烷-2-甲酰胺的药物组合物 | |
| RU2009111378A (ru) | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5 | |
| JP2011524896A5 (https=) | ||
| JP2023531863A (ja) | 肺の機械的損傷によって促進される肺線維症状態の治療で使用するためのニューロキニン（ｎｋ）－１受容体拮抗薬 | |
| JP2017519760A5 (https=) | ||
| JP2009514910A5 (https=) | ||
| JP6890540B2 (ja) | 肺高血圧症のための併用療法 | |
| EP2425830A1 (en) | Synergistic drug combination for the treatment of cancer | |
| JP2006505582A5 (https=) | ||
| US20190371469A1 (en) | Method of Identifying a Subgroup of Patients Suffering from DcSSc which Benefits from a Treatment with sGC Stimulators and sGC Activators in a Higher Degree than a Control Group | |
| JP4533590B2 (ja) | 脊髄損傷患者における疼痛又は痙性軽減用医薬組成物 | |
| Zhu et al. | ANTI-HBV ACTIVITY OF IN VITRO COMBINATIONS OF TENOFOVIR WITH NUCLEOSIDE ANALOGS: 172 | |
| Ghauri et al. | Pulmonary Hypertension in Systemic Sclerosis | |
| Yaremko et al. | Features of the laparoscopic cholecystectomy in patients with pneumoconiosis | |
| Vasakova et al. | Current and Future Therapies for Idiopathic Pulmonary Fibrosis | |
| Palmieri et al. | Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int |